Search

Home > GRACEcast > How Do the New ALK Inhibitor Drugs Compare to Xalkori (Crizotinib) for ALK+ Lung Cancer Patients?
Podcast: GRACEcast
Episode:

How Do the New ALK Inhibitor Drugs Compare to Xalkori (Crizotinib) for ALK+ Lung Cancer Patients?
Category: Science & Medicine
Duration: 00:04:58
Publish Date: 2014-05-29 19:00:00
Description:

Xalkori (crizotinib) has had great success treating ALK positive lung cancer patients. The next generation of ALK inhibitors are also showing great promise. In this video, Dr. Leena Gandhi of Dana-Farber Cancer Institute talks about the research.
Total Play: 0